TCT 2024 Late-Breaking Science Collection
Published: 17 October 2024
-
Views:
2697
-
Likes:
7
-
Views:
2697
-
Likes:
7
-
Up Next -
3m 43s -
3m 33s -
3m 56s -
6m 32s
-
6m 24sPart 3 | Session 1 5 Trials That Will Change My Practice with Dr Mirvat Alasnag -
5m 1sPart 3 | Session 2 2 Trials That Will Change My Practice with Dr Sahil Parikh
-
38m 7sPart 1 View from the Thoraxcenter: TCT 24 Late-breaking Preview Nicolas M Van Mieghem, Joost Daemen
-
7m 10sPart 2 | Session 1 SIRONA: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery Ulf Teichgräber
-
4m 10sPart 2 | Session 2 TAVR UNLOAD: Transcatheter Aortic Valve Replacement in Patients with Heart Failure and Moderate Aortic Stenosis Nicolas M Van Mieghem
-
4m 19sPart 2 | Session 3 EVOLVED: Early Intervention in Patients with Asymptomatic Severe Aortic Stenosis and Left Ventricular Decompensation Marc Dweck
-
5m 36sPart 2 | Session 4 MATTERHORN: Transcatheter Repair Versus Surgery in Mitral Regurgitation Stephan Baldus
Overview
Keep informed with our video collection unveiling data from the Transcatheter Cardiovascular Therapeutics Conference in Washington. With expert insights on late-breaking trials and critical findings, you won't want to miss our #TCT24 coverage.
- For practice-focused reviews of the most anticipated trials, watch our recurring View From the Thoraxcenter series, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Our short Expert Interviews with select faculty offer focused data analysis and take-home messages for practice.
- To delve deeper into insights on the most pertinent trials, catch our Highlights.
Dive into the latest cardiology research with our upcoming TCT Conference coverage.
More from this programme
Part 1
View From the Thoraxcenter: What's Hot at TCT 24?
Part 2
Expert Interviews
About the episode
TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.
Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).
INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients with complex lesion subsets were randomized 1:1 to receive either the DynamX Bioadaptor (Elixir Medical Corporation) or the Resolute Onyx (Medtronic) drug-eluting stent. 2400 patients in Sweden were enrolled in the trial, and were followed-up by phone at 30 days and 1 year, and by clinical and diagnostic registries at 6 months and 2 to 5 years. The primary outcome measure was target lesion failure (TLF) at one year.
Findings showed low and non-inferior TLF rates at 12 months, and significant reduction in TLF and TVF, with a flattening of event curves after 6 months. There was a substantial clinical benefit for high-risk subgroups including acute coronary syndrome after 6 months, and consistent effect across those prespecified subgroups.
Interview Questions:
1. What's the reasoning behind this trial?
2. What was the study design and the patient population?
3. What were your key findings?
4. What are the take-home messages for practice?
5. What further study is needed?
Recorded at TCT Conference in Washington, 2024.
Editor: Jordan Rance
Video Specialist: Dan Brent and Oliver Miles
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
David Erlinge
Head of the Cardiology Department
Prof David Erlinge is Head of the Cardiology Department at Skane University Hospital, Lund, SE. He graduated in medicine from the University of Lund, in 1990, where he also earned his Ph.D.
In 2006 he received the Lars Werkö distinguished research fellowship and was appointed Professor in Cardiology at Lund University in 2008.
Prof Erlinge’s clinical specialty is invasive cardiology (PCI) and his main research interests include acute coronary syndromes, platelet function, and cardioprotection.
Comments